Abaxis (ABAX) Given Daily News Sentiment Score of 0.18

Headlines about Abaxis (NASDAQ:ABAX) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 45.9447521699393 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Abaxis traded down $0.21, hitting $83.00, during midday trading on Monday, Marketbeat reports. The company’s stock had a trading volume of 2,990 shares, compared to its average volume of 256,381. Abaxis has a 12 month low of $43.66 and a 12 month high of $83.98. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of 64.36, a PEG ratio of 5.15 and a beta of 1.25.

Abaxis (NASDAQ:ABAX) last posted its quarterly earnings results on Thursday, April 26th. The medical research company reported $0.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.10. Abaxis had a return on equity of 10.65% and a net margin of 11.11%. The business had revenue of $67.90 million during the quarter, compared to the consensus estimate of $66.02 million. During the same period in the prior year, the company posted $0.33 EPS. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. equities analysts predict that Abaxis will post 1.48 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 15th. Shareholders of record on Friday, June 1st were paid a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.87%. This is an increase from Abaxis’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, May 31st. Abaxis’s dividend payout ratio is presently 55.81%.

Several equities research analysts recently issued reports on ABAX shares. ValuEngine raised shares of Abaxis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research lowered shares of Abaxis from a “strong-buy” rating to a “hold” rating in a report on Monday, April 30th. Stifel Nicolaus upped their price target on Abaxis from $57.00 to $62.00 and gave the stock a “hold” rating in a research note on Friday, April 27th. Credit Suisse Group upgraded Abaxis from an “underperform” rating to a “neutral” rating in a research note on Wednesday, May 16th. Finally, Sidoti downgraded Abaxis from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 16th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $63.50.

In other news, Director Prithipal Singh sold 20,000 shares of the stock in a transaction that occurred on Friday, May 18th. The stock was sold at an average price of $83.31, for a total transaction of $1,666,200.00. Following the completion of the transaction, the director now directly owns 38,400 shares in the company, valued at approximately $3,199,104. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Achim Henkel sold 8,000 shares of the stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $83.00, for a total value of $664,000.00. Following the transaction, the insider now owns 70,950 shares of the company’s stock, valued at $5,888,850. The disclosure for this sale can be found here. Insiders sold a total of 35,533 shares of company stock valued at $2,865,968 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Abaxis Company Profile

Abaxis, Inc develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

Insider Buying and Selling by Quarter for Abaxis (NASDAQ:ABAX)

Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply